Athira Pharma (NASDAQ:LONA) CEO Mark James Litton Sells 5,156 Shares

Athira Pharma, Inc. (NASDAQ:LONA) CEO Mark James Litton sold 5,156 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $5.37, for a total transaction of $27,687.72. Following the completion of the transaction, the chief executive officer directly owned 57,926 shares of the company’s stock, valued at approximately $311,062.62. The trade was a 8.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Athira Pharma Price Performance

Shares of Athira Pharma stock traded up $0.08 during trading on Friday, reaching $5.45. The stock had a trading volume of 9,148 shares, compared to its average volume of 65,726. The firm has a market cap of $21.49 million, a price-to-earnings ratio of -0.56 and a beta of 2.68. Athira Pharma, Inc. has a 52 week low of $2.20 and a 52 week high of $8.36.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on LONA shares. Mizuho upgraded shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective on the stock in a report on Thursday, February 19th. Cantor Fitzgerald assumed coverage on shares of Athira Pharma in a research report on Thursday, February 26th. They issued an “overweight” rating for the company. Weiss Ratings started coverage on shares of Athira Pharma in a research report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Wall Street Zen cut Athira Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Zacks Research raised Athira Pharma to a “hold” rating in a research report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.